# Claims

1. A pharmaceutical, which comprises a combination of

(A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and

(B) sitagliptin.

2. The use of a combination of:

(A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and

(B) sitagliptin,

in the manufacture of a medicament for prevention or treatment of diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are to be administered to a patient in need thereof either simultaneously or separately.

3. The use according to claim 2, wherein diabetes mellitus is type 2 diabetes.

4. The use according to claim 2 or 3, wherein the complication of diabetes mellitus is diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cerebrovascular disorder, ischemic cardiac disease, or peripheral arterial disease.